CLYM - Climb Bio Inc

https://climbbio.com

Momentum: Bearish

Recent News

No recent news found.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. The company is headquartered in Wilmington, Delaware.

52W High

$8.79

52W Low

$1.05

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.04

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.59

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.87

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

8.19%

Institutions (25–75% balanced)

81.78%

Shares Outstanding

67,764,000

Float

25,579,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-0.02

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.23%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.1785

0.2045

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025